acquired in-process research and development ("IPR&D") related to the
acquisitions of Alantos and Ilypsa in 2007.
(k) To exclude the impairment of a non-ENBREL related intangible asset
previously acquired in the Immunex acquisition.
(l) To exclude the impact of writing-off the cost of a semi-completed
manufacturing asset that will not be used due to a change in
(m) To exclude merger related expenses incurred due to the Abgenix
acquisition, primarily related to incremental costs associated with
recording inventory acquired at fair value which is in excess of our
(n) To exclude the pro rata portion of the deferred financing and related
costs that were immediately charged to interest expense as a result of
certain holders of our convertible notes due in 2032 exercising their
March 1, 2007 put option and the related convertible notes being
repaid in cash.
(o) To reflect the tax effect of the above adjustments for 2008, excluding
(1) certain components of the write-off of inventory (see (b) above),
(2) certain of the restructuring charges (see (e) above), (3) certain
of the loss accruals for settlements of commercial legal proceedings
(see (f) above) and (4) certain components of the loss accrual on the
sale of certain less significant marketed products and related assets
(see (g) above).
(p) To exclude the income tax benefit recognized as the result of
resolving certain non-routine transfer pricing issues with the
Internal Revenue Service ("IRS") for prior periods.
(q) To reflect the tax effect of the above adjustments for 2007, excluding
(1) certain of the restructuring charges (see(e) above), (2) certain
components of t
Copyright©2008 PR Newswire.
All rights reserved